Private Capital
Due diligence of a branded generic pharmaceuticals player
03 Mar 2020
Context
- Deal type: Growth
- Deal size: US$ 50 - 100M
- CDD duration: 4 weeks
Key Findings
- Strong historical growth across the therapeutic areas
- Fast growing addressable market driven by greater disease incidence
- First line of therapy in multiple TAs with positive feedback on efficacy
- Superior NPS, high brand awareness and strong ability to gain prescription share
- Deep distribution network, high coverage, and growing productivity of MRs
- Pricing leverage with less contribution to top line from drugs under NLEM, and ability to create formulations outside the DPCO purview
- Clear advantages / moats built through tight vertical integration allowing for faster product development
Key Insights / Outcomes
Mapped the entire universe of doctors by therapeutic area
Showed ramp up in revenue with increasing coverage by MRs in district
Praxis Differentiated Approach- Interviews with 100 MRs and 150 GPs/specialists
- Deep assessment of R&D capabilities and
product pipeline
- Deep assessment of MR coverage and
productivity
Are you looking to grow faster than the competition? Write to us below.